In vitro: increase TJ protein expression (ZO‐1, Claudin‐1, Occludin), keep epithelial barrier integrity, and lower permeability; In vivo: alleviate colitis, reduce IL‐6 expression, activate ERK, and TOR signaling pathways. This evidence concerns the gene OCLN and colitis.